Literature DB >> 19133923

Update on the evaluation of hypersensitivity reactions to betalactams.

M Blanca1, A Romano, M J Torres, J Férnandez, C Mayorga, J Rodriguez, P Demoly, P J Bousquet, H F Merk, M L Sanz, H Ott, M Atanasković-Marković.   

Abstract

Hypersensitivity reactions to betalactams (BLs) are classified as immediate or nonimmediate. The former usually appear within 1 h of drug-intake and are mediated by specific IgE-antibodies. Nonimmediate reactions are those occurring more than 1 h after drug-intake, and they can be T-cell mediated. The diagnostic evaluation of allergic reactions to BLs has changed over the last 5 years, for several reasons. Major and minor determinants are no longer commercially available for skin testing in many countries. In immediate allergic reactions, the sensitivity of skin testing and immunoassays is decreasing and new in vitro methods, such as the basophil activation test, are gaining importance for diagnosis. For nonimmediate reactions, skin testing appears to be less sensitive than previous results, although more studies need to be carried out in this direction. Nevertheless, the drug provocation test is still necessary for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133923     DOI: 10.1111/j.1398-9995.2008.01916.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  61 in total

1.  Positive serum specific IgE has a short half-life in patients with penicillin allergy and reversal does not always indicate tolerance.

Authors:  Janni Hjortlund; Charlotte Gotthard Mortz; Tore Bjerregaard Stage; Per Stahl Skov; Ronald Dahl; Carsten Bindslev-Jensen
Journal:  Clin Transl Allergy       Date:  2014-10-29       Impact factor: 5.871

Review 2.  Antibiotic Allergy in Pediatrics.

Authors:  Allison Eaddy Norton; Katherine Konvinse; Elizabeth J Phillips; Ana Dioun Broyles
Journal:  Pediatrics       Date:  2018-05       Impact factor: 7.124

Review 3.  Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

Authors:  Jason Trubiano; Elizabeth Phillips
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

Review 4.  Peri-operative anaphylaxis.

Authors:  Linda Nel; Efrem Eren
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

5.  Intentional rechallenge: does the benefit outweigh the risk?

Authors:  Vid Stanulović; Mauro Venegoni; Brian Edwards
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

6.  Diagnostic evaluation and risk factors for drug allergies in children: from clinical history to skin and challenge tests.

Authors:  Tugba Arikoglu; Gulen Aslan; Sehra Birgul Batmaz; Gulcin Eskandari; Ilter Helvaci; Semanur Kuyucu
Journal:  Int J Clin Pharm       Date:  2015-03-31

Review 7.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

8.  Return to sender: the need to re-address patient antibiotic allergy labels in Australia and New Zealand.

Authors:  J A Trubiano; L J Worth; K Urbancic; T M Brown; D L Paterson; M Lucas; E Phillips
Journal:  Intern Med J       Date:  2016-11       Impact factor: 2.048

Review 9.  [Systemic therapy with anti-infective agents. Principles of rational use of systemic antibiotics in dermatology].

Authors:  C Sunderkötter; R Brehler; K Becker
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

10.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.